LadRx Corp (LADX)

LadRx Corp is a biotechnology company focused on research and development of chemotherapeutic drugs for solid tumors in the United States. The company’s work is centered on its linker activated drug releases, or LADR, platform, which uses an organic backbone attached to a chemotoxic agent designed to target tumor tissue and release the agent within the tumor environment. Its development portfolio includes lead candidates LADRs 7, 8, 9, and 10, which incorporate novel auristatin and maytansinoid derivatives, as well as aldoxorubicin, a program in phase II clinical development for pancreatic cancer. LadRx also develops an albumin companion diagnostic, ACDx, intended to identify patients with cancer who may benefit from treatment with the four lead LADR candidates. The company, formerly known as CytRx Corporation, adopted the LadRx Corporation name in September 2022 and is headquartered in Los Angeles, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.